Last update: Aug. 6, 2017

Miglitol

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

Alpha-glucosidase inhibitor which acts within the gastrointestinal tract without being absorbed, reducing intestinal absorption of glucose. Very low risk of hypoglycemia in monotherapy.

Miglitol is excreted in breast milk in minute quantities (Serrano 2014, Pfizer 2012, AEMPS 2009) reaching a relative dose much less than 1%.

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Miglitol in other languages or writings:

Tradenames

Main tradenames from several countries containing Miglitol in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 - 70 %
Molecular weight 207 daltons
Protein Binding < 4 %
VD 0,18 l/Kg
Tmax 2 - 3 hours
T1/2 2 - 3 hours
Relative Dose 0,4 %

References

  1. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Abstract

Total visits

2,872

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM